NO20051059L - Myokardiell perfusjonsavbildning ved a benytte A2A-reseptoragonister - Google Patents

Myokardiell perfusjonsavbildning ved a benytte A2A-reseptoragonister

Info

Publication number
NO20051059L
NO20051059L NO20051059A NO20051059A NO20051059L NO 20051059 L NO20051059 L NO 20051059L NO 20051059 A NO20051059 A NO 20051059A NO 20051059 A NO20051059 A NO 20051059A NO 20051059 L NO20051059 L NO 20051059L
Authority
NO
Norway
Prior art keywords
receptor agonists
myocardial perfusion
perfusion imaging
myocardial
myocardial imaging
Prior art date
Application number
NO20051059A
Other languages
English (en)
Norwegian (no)
Inventor
Luiz Belardinelli
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20051059L publication Critical patent/NO20051059L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/507—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for determination of haemodynamic parameters, e.g. perfusion CT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20051059A 2002-07-29 2005-02-25 Myokardiell perfusjonsavbildning ved a benytte A2A-reseptoragonister NO20051059L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39917702P 2002-07-29 2002-07-29
US39917602P 2002-07-29 2002-07-29
US42690202P 2002-11-15 2002-11-15
US45980303P 2003-04-02 2003-04-02
PCT/US2003/023511 WO2004011010A1 (en) 2002-07-29 2003-07-29 Myocardial perfusion imaging using a2a receptor agonists

Publications (1)

Publication Number Publication Date
NO20051059L true NO20051059L (no) 2005-02-25

Family

ID=31192376

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051059A NO20051059L (no) 2002-07-29 2005-02-25 Myokardiell perfusjonsavbildning ved a benytte A2A-reseptoragonister

Country Status (12)

Country Link
US (2) US7683037B2 (enExample)
EP (1) EP1524984A1 (enExample)
JP (1) JP2005538190A (enExample)
KR (1) KR20050026546A (enExample)
CN (1) CN1671399A (enExample)
AU (1) AU2003259264A1 (enExample)
CA (1) CA2492855C (enExample)
IL (1) IL166555A0 (enExample)
MX (1) MXPA05001123A (enExample)
NO (1) NO20051059L (enExample)
NZ (1) NZ537975A (enExample)
WO (1) WO2004011010A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
CA2439222C (en) 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
AU2003259264A1 (en) 2002-07-29 2004-02-16 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
WO2005013801A2 (en) * 2003-07-18 2005-02-17 Munn Charles S Enhanced cardiac radionuclide imaging techniques
WO2005082379A1 (en) * 2004-01-27 2005-09-09 Cv Therapeutics, Inc. Myocardial perfusion imaging using adenosine receptor agonists
JP2008517063A (ja) * 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
US7381714B2 (en) * 2005-05-19 2008-06-03 Cv Therapeutics, Inc. A1 adenosine receptor agonists
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
EP2068850A1 (en) * 2006-06-22 2009-06-17 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CN101511366B (zh) * 2006-09-01 2011-12-28 吉利德帕洛阿尔托股份有限公司 在心肌显像方法期间用于增加患者耐受性的方法和组合物
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
EP2099360A2 (en) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
WO2010037122A1 (en) * 2008-09-29 2010-04-01 Gilead Palo Alto, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods
US11730430B2 (en) * 2012-09-21 2023-08-22 The General Hospital Corporation System and method for single-scan rest-stress cardiac pet
EP2908858B1 (en) 2012-10-19 2020-06-24 New York University Compositions for use in inhibiting osteolysis
WO2014083580A2 (en) * 2012-11-30 2014-06-05 Leiutis Pharmaceuticals Pvt. Ltd. Pharmaceutical compositions of regadenoson
CN105997852B (zh) * 2016-05-15 2018-10-09 南京海融医药科技股份有限公司 一种瑞加诺生注射液及其制备方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK135130B (da) 1970-12-28 1977-03-07 Takeda Chemical Industries Ltd Analogifremgangsmåde til fremstilling af 2-substituerede adenosinderivater eller syreadditionssalte deraf.
BE787064A (fr) 1971-08-03 1973-02-01 Philips Nv Dispositif magnetique comportant des domaines
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4120947A (en) 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
US4089959A (en) 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
SE7810946L (sv) 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4593095A (en) 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4696932A (en) 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
JPS6299395A (ja) * 1985-10-25 1987-05-08 Yamasa Shoyu Co Ltd ２−アルキニルアデノシンおよび抗高血圧剤
US4968697A (en) * 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5070877A (en) 1988-08-11 1991-12-10 Medco Research, Inc. Novel method of myocardial imaging
EP0444196B1 (en) * 1988-11-15 1994-06-08 Yamasa Shoyu Kabushiki Kaisha Agent for treatment and prophylaxis of ischemic disease of heart or brain
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
EP0429681B1 (en) * 1989-06-20 1995-09-06 Yamasa Shoyu Kabushiki Kaisha (Yamasa Corporation) Intermediate for 2-alkynyladenosine synthesis, production of said intermediate, production of 2-alkynyladenosine from said intermediate, and stable 2-alkynyladenosine derivative
US5032252A (en) * 1990-04-27 1991-07-16 Mobil Oil Corporation Process and apparatus for hot catalyst stripping in a bubbling bed catalyst regenerator
DE4019892A1 (de) 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
US5189027A (en) * 1990-11-30 1993-02-23 Yamasa Shoyu Kabushiki Kaisha 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases
FR2671356B1 (fr) 1991-01-09 1993-04-30 Inst Nat Sante Rech Med Procede de description des repertoires d'anticorps (ab) et des recepteurs des cellules t (tcr) du systeme immunitaire d'un individu.
JP2740362B2 (ja) * 1991-02-12 1998-04-15 ヤマサ醤油株式会社 安定な固体状２‐オクチニルアデノシンおよびその製造法
JP3053908B2 (ja) 1991-06-28 2000-06-19 ヤマサ醤油株式会社 ２‐アルキニルアデノシン誘導体
US5516894A (en) 1992-03-11 1996-05-14 The General Hospital Corporation A2b -adenosine receptors
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
JPH08500967A (ja) 1992-06-12 1996-02-06 ガーヴァン インスティチュート オブ メディカル リサーチ ヒトＡ１，Ａ２ａおよびＡ２ｂアデノシン受容体をエンコードするＤＮＡ配列
EP0601322A3 (en) * 1992-10-27 1994-10-12 Nippon Zoki Pharmaceutical Co Adenosine deaminase inhibitor.
CA2112031A1 (en) 1992-12-24 1994-06-25 Fumio Suzuki Xanthine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE69526822T2 (de) 1994-02-23 2003-01-23 Kyowa Hakko Kogyo K.K., Tokio/Tokyo Xanthin-derivate
US5704491A (en) 1995-07-21 1998-01-06 Cummins-Allison Corp. Method and apparatus for discriminating and counting documents
US5646156A (en) 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US6448235B1 (en) * 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) * 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US5877180A (en) * 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
US5854081A (en) 1996-06-20 1998-12-29 The University Of Patent Foundation Stable expression of human A2B adenosine receptors, and assays employing the same
US5780481A (en) 1996-08-08 1998-07-14 Merck & Co., Inc. Method for inhibiting activation of the human A3 adenosine receptor to treat asthma
US5776960A (en) 1996-10-16 1998-07-07 Buckman Laboratories International, Inc. Synergistic antimicrobial compositions containing an ionene polymer and a pyrithione salt and methods of using the same
US5770716A (en) * 1997-04-10 1998-06-23 The Perkin-Elmer Corporation Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same
AU7449598A (en) 1997-05-23 1998-12-11 Nippon Shinyaku Co. Ltd. Medicinal composition for prevention or treatment of hepatopathy
CA2295195C (en) 1997-06-18 2009-12-15 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
US6026317A (en) * 1998-02-06 2000-02-15 Baylor College Of Medicine Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
WO1999063938A2 (en) 1998-06-08 1999-12-16 Epigenesis Pharmaceuticals, Inc. Composition and method for prevention and treatment of cardiopulmonary and renal failure or damage associated with ischemia, endotoxin release, ards or brought about by administration of certain drugs
US6322771B1 (en) * 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6368573B1 (en) * 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6677336B2 (en) * 2000-02-22 2004-01-13 Cv Therapeutics, Inc. Substituted piperazine compounds
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
CA2439222C (en) * 2000-02-23 2009-07-14 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US6387913B1 (en) 2000-12-07 2002-05-14 S. Jamal Mustafa Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists
US6670334B2 (en) * 2001-01-05 2003-12-30 University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
US6995148B2 (en) * 2001-04-05 2006-02-07 University Of Pittsburgh Adenosine cyclic ketals: novel adenosine analogues for pharmacotherapy
US6599283B1 (en) * 2001-05-04 2003-07-29 Cv Therapeutics, Inc. Method of preventing reperfusion injury
US7109203B2 (en) * 2001-05-14 2006-09-19 Novartis Ag Sulfonamide derivatives
US20030235555A1 (en) 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
RU2318824C2 (ru) 2001-11-09 2008-03-10 Си Ви Терапьютикс, Инк. Антагонисты рецептора аденозина a2b, фармацевтическая композиция на их основе и способ их получения
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
BR0215202A (pt) 2001-12-20 2004-10-13 Osi Pharm Inc Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
AU2003259264A1 (en) 2002-07-29 2004-02-16 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
WO2005082379A1 (en) 2004-01-27 2005-09-09 Cv Therapeutics, Inc. Myocardial perfusion imaging using adenosine receptor agonists
NZ589657A (en) 2004-10-15 2012-06-29 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
JP2008517063A (ja) * 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
JP2008527003A (ja) 2005-01-12 2008-07-24 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド 喘息又は気管支痙攣の既往歴を有する患者における心筋機能不全を検出する方法
WO2007092372A1 (en) 2006-02-03 2007-08-16 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
EP2068850A1 (en) * 2006-06-22 2009-06-17 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
CN101511366B (zh) * 2006-09-01 2011-12-28 吉利德帕洛阿尔托股份有限公司 在心肌显像方法期间用于增加患者耐受性的方法和组合物
US20090081120A1 (en) 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
CA2663361A1 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
EP2099360A2 (en) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
WO2010037122A1 (en) 2008-09-29 2010-04-01 Gilead Palo Alto, Inc. Combinations of a rate control agent and an a-2-alpha receptor antagonist for use in multidetector computed tomography methods

Also Published As

Publication number Publication date
US8183226B2 (en) 2012-05-22
WO2004011010A1 (en) 2004-02-05
US7683037B2 (en) 2010-03-23
CA2492855A1 (en) 2004-02-05
NZ537975A (en) 2007-08-31
JP2005538190A (ja) 2005-12-15
US20040064039A1 (en) 2004-04-01
CA2492855C (en) 2012-09-18
IL166555A0 (en) 2006-01-15
US20100272645A1 (en) 2010-10-28
AU2003259264A1 (en) 2004-02-16
EP1524984A1 (en) 2005-04-27
MXPA05001123A (es) 2005-04-29
CN1671399A (zh) 2005-09-21
KR20050026546A (ko) 2005-03-15

Similar Documents

Publication Publication Date Title
NO20051059L (no) Myokardiell perfusjonsavbildning ved a benytte A2A-reseptoragonister
NO20072540L (no) Anvendelse av A2A-adenosinreseptoragonist
TR200200588T2 (tr) N-pirazol A2A reseptör agonistleri
CY1114928T1 (el) Απεικονιση μυοκαρδιακης αιματωσης χρησιμοποιωντας αγωνιστες υποδοχεα αδενοσινης
BRPI0512193A (pt) entidade quìmica, composição farmacêutica, métodos de tratamento de doença cardìaca, para modular o sarcÈmero cardìaco, e para potencializar miosina cardìaca em um mamìfero, uso de uma entidade quìmica, e, método de preparação de um composto
DOP2006000008A (es) Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EA201000211A1 (ru) Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
NO20074295L (no) Substituerte gamma lactamer som terapeutiske midler
DK1189629T3 (da) Peptid YY (PYY) til behandling af glucosestofskiftesygdomme
NO20056048L (no) Pan-Kirk2dl nk-receptor antibodies and their use in diagnostik and therapy
EA021242B9 (ru) Антитела к остеопротегерин лиганду (опгл)
NO20073487L (no) Valg av pasienter for terapi med en HER-inhibitor
PE20080748A1 (es) Vacuna a base de los de cepas de neisseria
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
BR112015002249A2 (pt) composto, um estereoisômero ou sal farmaceuticamente aceitável do mesmo; composição farmacêutica; método para tratar um estado associado a receptor de adenosina a2a em um indivíduo; método para diagnosticar anormalidades de perfusão de miocárdio em um mamífero; e método para reduzir a pressão interocular em um indivíduo
WO2001062979A3 (en) Dentification of partial agonists of the a2a adenosine receptor
NO20072290L (no) Organiske forbindelser.
AR024440A1 (es) AGONISTAS DEL RECEPTOR A2A DE ETER PROPARGIL FENILICO, COMPOSICIoN FARMACEUTICA Y EL USO DE LOS MISMOS PARA PREPARAR UN MEDICAMENTO.
NO20071613L (no) Forbindelser for myokardial perfusjons-billeddannelse
WO2005065668A3 (en) Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
EA200500005A1 (ru) Способ лечения повреждения, вызванного реперфузией после ишемии, с использованием антагонистов рецептора аденозина
NZ516336A (en) Thiophene A2A receptor agonists
HUP0400758A2 (hu) Kardiális perfúzió és kardiális inflammáció egyidejű duális izotópos leképezése
ATE516011T1 (de) Pharmazeutische zusammensetzungen eines a2a rezeptorantagonisten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application